Compare Marsh & McLennan Companies, Inc. (MRSH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.04 (market cap $87.77B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 57.4× Recursion Pharmaceuticals Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MRSH | RXRX | |
|---|---|---|
Market Cap | $87.77B | $1.53B |
Sector | Financials | Health |
52-Week High | $211.21 | $6.79 |
52-Week Low | $157.32 | $2.84 |
Enterprise Value | $108.61B | $946.50M |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $181.59, down 0.32% on the day, with a bullish technical signal from moving averages and support at $180. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS versus $2.88 expected, driven by 6% revenue growth to $7.4 billion. Fundamentals show robust profitability with a 14.26% net margin and 27.42% ROE, while valuation ratios like P/E of 22.77 and P/S of 3.26 reflect premium pricing. Recent news highlights a 10% dividend increase to $0.99 per share, payable in August 2026.
The outlook for MRSH is positive, supported by consistent earnings beats and strategic AI investments, but risks include rising operating expenses and softer insurance pricing. Analysts maintain a consensus price target of $203.75, implying 12% upside, with 11 buy ratings outweighing 1 sell. Investors should monitor expense management and organic growth sustainability amid competitive pressures.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
